Drug intelligence / Profile preview

SHX-001

Development stage: Phase 1
Lead developer: Shenox Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

SHX-001 is an investigational transdermal patch formulation of racemic ketamine being developed by Shenox Pharmaceuticals for the treatment of major depressive disorder (MDD). As an N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine exerts rapid-acting antidepressant effects. SHX-001 is designed to provide a gradual and prolonged ascending pharmacokinetic profile via precise transdermal delivery, aiming to minimize the adverse events (such as dissociation) and addiction potential typically associated with intravenous or intranasal administration. It is currently in Phase 1 clinical development for patients with sub-optimally responsive MDD.

Other names: ketamine transdermal patchketamine TDDS

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on SHX-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHX-001.

Explore the full profile